FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APP	ROVAL
OMB Number:	3235-0287
Estimated average	burden

. _ _ _ _

to Sec obligation	this box if no lo tion 16. Form 4 tions may contin tion 1(b).	or Form 5	STATE		-			-	_		NEFICIA	_		RSHIP	Estim	Number: ated average bu per response:	3235-0287 rden 0.5	
or Sec 1. Name and Address of Reporting Person* 2. Issue					ursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 2. Issuer Name and Ticker or Trading Symbol <u>Black Diamond Therapeutics, Inc.</u> [BDTX]						5.	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner Officer (give title Other (specify below) below)						
ARA HILL TOP BUILDING, UNIT A-5, PLETTERIJWEG OOST 1					3. Date of Earliest Transaction (Month/Day/Year) 10/31/2022									,		,		
(Street) CURACAO P8 00000						If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person X Form filed by More than One Reporting Person				
(City)	(01	, ,		Deriva	tive S	Secu	ritios		wirod	Die	nosed of	or Be	nefici	ally Owr				
Table I - Non-Derivat 1. Title of Security (Instr. 3) 2. Transacting Date (Month/Day) 2. Month/Day)				tion 2A. Deemed Execution Date,		3. Transa Code (8)	ction	4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)		d (A) or	5. Amount of		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
			2022				Code	v	Amount 99,801	(A) or (D)	Price	Trans (Instr.	action(s) 3 and 4)	D				
Common Stock 10/31/2022 Table II - Derivative Sect								A		Diam		A	\$2.25		377,839			
		Idi									convertib				u			
1. Title of Derivative Security (Instr. 3)	tive Conversion Date Execution Date, Tra by or Exercise (Month/Day/Year) if any Co		Transaction of Code (Instr. Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)						
				Code V			(A)	(D)	Date Exercis	sable	Expiration Date		Amount or Number of Shares					
1. Name and Address of Reporting Person [*] BIOTECH GROWTH N V																		
		(First) JILDING, UNIT OOST 1	(Middle CA-5,	e)		_												
(Street) CURAC	AO	P8	00000)														
(City)		(State)	(Zip)															
	nd Address of OTECH A	Reporting Person [*]																
(Last) SCHWE	RTSTRAS	(First) SE 6	(Middle	e)														

(City) (State) (Zip)

Explanation of Responses:

SCHAFFHAUSEN V8

Remarks:

(Street)

Biotech Growth N.V. is a wholly-owned subsidiary of BB Biotech AG. Accordingly, BB Biotech AG may be deemed to be the indirect beneficial owner of the securities of Black Diamond Therapeutics, Inc. held directly or indirectly by Biotech Growth N.V. This Form 4 is filed jointly by BB Biotech AG and Biotech Growth N.V.



Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

CH-8200

11/02/2022 Date

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.